ASCO 2020：11项中国研究入选为口头报告，17项Poster报告

受全球新冠疫情受到影响，预定于5月29日~6月2日在芝加哥举行的英国临床学术委员会（ASCO）年会今年将首次以新线上表达方式举办，这是迄今为止最大规模的新线上盛会。今天，全体会议的概要题目定为，共103个sessions，中的国共约11项研究工作入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

硫替尼或拉帕替尼加卡培他滨运用于HER2+移出性乳腺胰脏（PHOEBE）：一项III期随机实验。

专场：移出性乳腺胰脏

笔记：中的国医学科学院所医院徐兵河系主任、马飞系主任，复旦大学附属所医院胡夕春系主任等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三同义乳腺胰脏标准疗法后卡培他滨保有人声化学治疗的III期实验（SYSUCC-001）。

专场：乳腺胰脏—局部/区外/专用疗法

笔记：中的山大学防治中的心中的山王树森系主任等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移出性神经的表型特征来预见神经脊液中的循环系统DNA检测的概率: 新工具牵制从前对手

专场：新工具解决从前解决办法

笔记：杨美芹 杨阿马等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对布基纳法索拉非尼作为中的叶肝细胞内胰脏的三新线疗法：一项全站标识、随机、多中的心II/III期实验。

专场：肠道胰脏—大肠腹腔、胰脏变和水火

笔记：四川大学索科利夫卡所医院毕锋系主任、中的国团结解放军南开所医院秦叔逵系主任等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国中的叶肝胰脏高血压阿帕替尼二新线疗法：一项随机、安慰剂对照、双盲III期研究工作

专场：肠道胰脏—大肠腹腔、胰脏变和水火

笔记：中的国团结解放军南开所医院秦叔逵系主任、四川大学索科利夫卡所医院杨秋系主任等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中的叶复发性卵巢胰脏二次细胞内减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

为题：医学胰脏症

笔记：复旦大学附属中的山所医院臧荣余系主任等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治性内膜切除术后专用疗法中的的序贯放化学治疗对比单独皮肤胰脏或并行放化学治疗（STARS研究工作）：一项随机、对照、全站标识的III期实验。

全体会议：医学胰脏症

笔记：中的山大学防治中的心马尔季尼夫卡系主任、刘继红系主任等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专用吉非替尼对比化学治疗运用于可切除的EGFR甲基化的N1-N2期NSCLC-随机III期临床实验的最终总体穴居深入研究。

为题：肺胰脏—非小细胞内局部-区外/小细胞内/其他胸部

笔记：广东省团结所医院吴一龙系主任等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR甲基化寡移出非小细胞内肺胰脏高血压三新线酪氨酸嘌呤胺为首或不为首积极前新线局部皮肤胰脏：III期全站标识临床随机实验（SINDAS）的中的期结果（NCT02893332）。

为题：肺胰脏-非小细胞内移出

笔记：绵阳市团结所医院曾铭系主任等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对比如说死亡-1（PD-1）的人源化IgG4单克隆抗体为首阿昔替尼运用于移出性黏膜黑色素肉瘤高血压的Ib期研究工作的总穴居期和生物；也深入研究。

为题：黑色素肉瘤/皮肤胰脏

笔记：北京大学所医院郭军、盛锡楠系主任等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：通用CAR-T细胞内首次化学物质实验疗法复发/难治性T细胞内急性淋巴细胞内肝癌（r/r T-ALL）的安全性和。全体会议：开发中的的疗法电子技术-免疫疗法。笔记：中的山李明欣等概要：3013月历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利霉素在中的叶腹腔鳞状细胞内胰脏高血压中的的运用于：一项随机的全站标识II期实验（ORIENT-2）。全体会议：肠道胰脏-大肠腹腔胰脏、胰脏变胰脏和水火道胰脏笔记：徐建明系主任等概要：4511月历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T细胞内对质母细胞内肉瘤的根治性疗法全体会议：骨骼肌笔记：代红久、孙斌、杨东、徐晖、顾华以、魏佳、徐旭东概要：2522月历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中的叶错配修复缺陷高血压中的的运用于全体会议：开发中的的疗法学-免疫疗法笔记：沈琳系主任等概要：3021月历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗法复发/难治性ACUTE淋巴细胞内肝癌/淋巴肉瘤的首例化学物质临床实验全体会议: 开发性疗法学-免疫疗法笔记简介：张明志，马如龙等概要：3026月历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 昂替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）为首应运用于中的叶实体肉瘤高血压的Ib期研究工作全体会议：发展性疗法学----分子可凋亡本品和微生物学笔记：龚继芳，沈琳系主任等概要：3523月历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin为首紫杉醇和nedaplatin疗法复发性或移出性腹腔鳞状细胞内胰脏（ESCC）高血压的II期研究工作。全体会议：肠道胰脏-大肠腹腔、胰脏变和水火道胰脏的研究工作笔记：中的山王志弱，杨玉红，中的山王德申，中的山王凤华，任超，谭琼 中的山王志弱、杨玉红、中的山王德深、中的山王凤华、任超、谭琼概要：4522月历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：肠道胰脏-大肠腹腔胰脏、胰脏变胰脏和水火管胰脏的二新线疗法笔记：宋艳等概要：4524月历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA分类器运用于初始活检时检测高等级胰脏的尿液外体环状RNA分类器：一项多中的心的回顾性研究工作全体会议：脊柱生殖系统胰脏症----胰脏、睾丸胰脏和胰脏笔记简介：Liaoyuan Li等概要：5522月历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部中的叶宫颈胰脏并作化学治疗后的专用化学治疗全体会议: 医学胰脏症笔记简介： 杨珉珉等概要：6031月历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法病变质性胰脏的相关性：基于ALTER01031实验的深入研究。会话：头颈部笔记：天津市所医院高明系主任概要：6526月历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和平均年龄对安洛替尼疗法后高血压结局的受到影响: ALTER01031的亚组深入研究全体会议：头颈部笔记：天津市所医院高明系主任概要：6527月历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预见I-IIIA期非小细胞内肺胰脏（NSCLC）高血压术后复发: GASTO1035和GASTO1018的结果全体会议：肺胰脏-非小细胞内局部-区外性/小细胞内/小细胞内/其他胸科胰脏症笔记：Si-Yu Wang等概要：9023月历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内肺胰脏（NSCLC）中的EGFR酪氨酸嘌呤胺的新型抗药性机制全体会议:肺胰脏-非小细胞内移出性肺胰脏笔记简介：徐昕，金结缘，满宇，欧娘子，华宝，薛武，杨少，范敏 徐昕、金结缘、满宇、欧娘子、华宝、薛武、杨绍、范敏概要：9528月历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验中的中的叶黑色素肉瘤总穴居的替代往南全体会议：黑色素肉瘤/皮肤胰脏笔记：聂润聪，袁书弱，杨元芳，陈英波，周志伟 聂润聪、袁书弱、杨元芳、陈英波、周志伟概要：10030月历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法复发或移出性原发性恶性骨高血压的II期研究工作全体会议： 肉肉瘤笔记：唐丽娜，牛晓辉，中的山王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、中的山朱高煦、蔡启庆、涂崇奇、范正福、杨瑶概要：11525月历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞扬安罗替尼在中的叶肉肉瘤高血压多新线疗法中的的安全性和。全体会议：肉肉瘤笔记：姚伟涛，中的山王家弱，王文，中的山李明，杜新辉，田志浩，牛晓颖 姚伟涛、中的山王家弱、王文、中的山王鑫、杜鑫辉、田志超、牛晓英概要：11526月历：414